stalled on glp 1 GLP-1 Weight Loss Plateau: Causes & Fixes Everyone wants GLP-1s to do

Terry Turner has been writing articles and producing news broadcasts for more than 30 years

Lecanemab and donanemab as therapies for Alzheimers disease: an illustrated perspective on the data

A 2011 TIME magazine report that surveyed 52,000 people and found that 25% of nonsmokers were obese compared with 17% of marijuana users

Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, et al

Ibrance (palbociclib) Disease area(s): Oncology Manufacturer(s): Pfizer 2024 Sales (USD): $4.37 billion Why it sold so well: Pfizers Ibrance generated $4.37 billion in global revenue in 2024, maintaining its position as a leading therapy for hormone receptor-positive (HR+), HER2-negative metastatic breast cancer